Celyad Oncology

IMMUNICY-1 Dose-Escalation Clinical Study

CYAD-211

Study Overview

- Three cohorts to define the recommended dose
- Dose levels to be investigated: $3x10^7$, $1x10^8$ and $3x10^8$ cells per infusion
- Infusion of CYAD-211 after preconditioning of cyclophosphamide (300 mg/m²) and fluradarabine (30 mg/m²)

Primary Objectives

- To determine the recommended dose of CYAD-211 after a nonmyeloablative preconditioning chemotherapy for patients with relapsed / refractory Multiple Myeloma

Secondary Objectives

- Safety
- Overall Response rate
- CYAD-211 cell expansion & persistence

Key Inclusion Criteria

- Multiple Myeloma with relapsed or refractory disease to at least two prior treatment regimens
- At least one complete cycle of treatment for each prior treatment regimen
- At least one response to a prior treatment regimen
- Measurable disease as per the International Myeloma Working Group (IMWG) Response Criteria

Treatment Schedule

Celyad Oncology

IMMUNICY-1 Dose-Escalation Clinical Study

CYAD-211

CYAD-211 Overview
Non-Gene Edited Allogeneic CAR T

- Second generation CAR targeting B Cell Maturation Antigen (BCMA)
- Truncated CD34 selection marker
- Single short hairpin RNA (shRNA) interferes with CD3ζ component of the T cell receptor (TCR) complex to reduce risk of graft versus host disease (GvHD)
- Single transduction to generate Allogeneic CAR T cells that avoids issues associated with multiple genetic manipulations
- All-in-One vector approach



This Study registered at NCT04613557

Celyad Oncology SA
Axis Business Park | Rue Edouard Belin 2 | 1450 Mont-Saint-Guibert | **Belgium**
+32 (0) 10 39 41 00 | +1 (857) 990-6900 | **info@celyad.com**